Consumer Advocacy Groups, Pharmaceutical Companies Debate Three-Year Marketing Exclusivity Period Awarded By FDA For Plan B

Main Category: Cancer / Oncology
Also Included In: Women's Health / Gynecology;  Pediatrics / Children's Health
Article Date: 15 Nov 2006 - 17:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


Consumer advocates and drug companies are debating FDA's decision to grant Barr Pharmaceuticals three years of regulatory exclusivity for its emergency contraceptive Plan B, which can prevent pregnancy if taken up to 72 hours after sexual intercourse, the Boston Globe reports. In exchange for exclusivity -- in which the drug will receive no generic competition for a certain period of time -- Barr must conduct a series of studies to determine how consumers use the product and how they understand the new label. Melissa Dunn, a spokesperson for GlaxoSmithKline Consumer Healthcare, said exclusivity provides "some incentive for innovation," adding, "It's really for companies who are doing all of the background research, investing the [research and development] dollars, and time and efforts into developing a product to give them some protection for a period of time." GSK received three years of exclusivity for over-the-counter sales of the smoking cessation drug Nicorette. Sidney Wolfe, director of the Health Research Group at Public Citizen, said the exclusivity means that consumers will have to pay more for the drug than they should, adding that pharmaceutical companies "should get some advantage for" their research, "but it seems like three years is on the long side." Democratic lawmakers, who will hold the majority in the 110th Congress, have said they will seek some restrictions in the methods drug makers use to keep generic competition off the market (Boston Globe, 11/13).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Nicorette.


Article adapted by Medical News Today from original press release.
Visit our cancer / oncology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Barbara Martin. "Consumer Advocacy Groups, Pharmaceutical Companies Debate Three-Year Marketing Exclusivity Period Awarded By FDA For Plan B." Medical News Today. MediLexicon, Intl., 15 Nov. 2006. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/56547.php>

APA
Barbara Martin. (2006, November 15). "Consumer Advocacy Groups, Pharmaceutical Companies Debate Three-Year Marketing Exclusivity Period Awarded By FDA For Plan B." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/56547.php.

Please note: If no author information is provided, the source is cited instead.


Cancer / Oncology

What is Cancer?

Cancer is a class of diseases characterized by out-of-control cell growth. There are over 100 different types of cancer, and each is classified by the type of cell that is initially affected. Read more...

Most Popular Articles



Follow Our Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cancer / Oncology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »